Transforming growth factor beta superfamily ligands (TGF-β ligands)

Transforming growth factor beta (TGF-β) superfamily ligands, specifically those targeted by modified Activin receptor type 2A (ActRIIA) fusion proteins, include Activin A, Activin B, and Growth Differentiation Factors such as GDF8 and GDF11. These ligands are critical regulators of cellular growth, differentiation, and tissue homeostasis, signaling primarily through the SMAD2/3 pathway (Humbert et al., 2021, Lancet Respir Med). In pathological states like pulmonary arterial hypertension (PAH), an overabundance of these ligands disrupts the balance with the pro-survival BMPR2/SMAD1/5/8 pathway, leading to maladaptive vascular remodeling and increased pulmonary arterial pressure (Hoeper et al., 2023, NEJM). Therapeutic intervention using a modified ActRIIA-Fc fusion protein, such as sotatercept, acts as a "ligand trap" to sequester these circulating factors before they can bind to their endogenous cell-surface receptors. This mechanism effectively rebalances the signaling environment, promoting vascular reverse remodeling and improving hemodynamic parameters (FDA, 2024, Winrevair Label). Beyond cardiovascular disease, these ligands are also involved in the regulation of erythropoiesis and bone density, making them relevant targets for treating anemia and musculoskeletal disorders.

Other names

Activin receptor type 2A ligandsActRIIA ligandsActivin AActivin BGrowth differentiation factor 11 (GDF11)Growth differentiation factor 8 (GDF8)Myostatin

Acts as a soluble decoy receptor (ligand trap) that binds and sequesters circulating TGF-β superfamily ligands, preventing them from interacting with endogenous cell-surface receptors and thereby rebalancing SMAD signaling pathways (Hoeper et al., 2023, NEJM).